Intranasal inhibitor broadly blocks SARS-CoV-2 including recent highly immunoevasive Omicron subvariants
A. R. Mäkelä, H. Ugurlu, L. Hannula, P. Salminen, R. Kant, R. Fagerlund, S. Mäki, A. Haveri, T. Strandin, L. Kareinen, J. Hepojoki, L. Levanov, A. Pasternack, R. A. Naves, O. Ritvos, , K. Saksela
This paper describes a novel intranasal inhibitor, TriSb92, that effectively neutralizes SARS-CoV-2 and recent Omicron subvariants, offering protection against infection in mice.
bioRxiv · Dec 28, 2021 · PreprintMicrobiology